StockData
Amgen Inc logo

Amgen Inc (AMGN) stock

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 17/3026% above fair value
$462.32−3.35 (-0.72%)

Close on Nov 16, 2026Market cap $249.95BP/E 26.8Yield 2.09%

Amgen r&d expenses

Research and development expenses are spending on new products and technology.

Amgen's R&D Expenses for the twelve months ending Sep 30, 2026 was $7.84B, up 14.4% year over year. For fiscal 2025 it was $7.27B, up 21.9% from the year before. Over ten years it grew 6.0% a year on average. The highest annual figure on record is $7.27B in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$7.27B+21.9%
FY2024Dec 31, 2024$5.96B+24.7%
FY2023Dec 31, 2023$4.78B+7.9%
FY2022Dec 31, 2022$4.43B-8.0%
FY2021Dec 31, 2021$4.82B+14.5%
FY2020Dec 31, 2020$4.21B+2.2%
FY2019Dec 31, 2019$4.12B+10.1%
FY2018Dec 31, 2018$3.74B+4.9%
FY2017Dec 31, 2017$3.56B-7.2%
FY2016Dec 31, 2016$3.84B-5.7%
FY2015Dec 31, 2015$4.07B-5.3%
FY2014Dec 31, 2014$4.30B+5.2%
FY2013Dec 31, 2013$4.08B+20.8%
FY2012Dec 31, 2012$3.38B+6.7%
FY2011Dec 31, 2011$3.17B+9.4%
FY2010Dec 31, 2010$2.89B+1.0%
FY2009Dec 31, 2009$2.86B-5.5%
FY2008Dec 31, 2008$3.03B-7.2%
FY2007Dec 31, 2007$3.27B–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$2.11B+11.1%
Q2 FY2026Jun 30, 2026$1.87B+7.1%
Q1 FY2026Mar 31, 2026$1.72B+15.7%
Q4 FY2025Dec 31, 2025$2.14B+24.2%
Q3 FY2025Sep 30, 2025$1.90B+31.0%
Q2 FY2025Jun 30, 2025$1.74B+20.5%
Q1 FY2025Mar 31, 2025$1.49B+10.6%
Q4 FY2024Dec 31, 2024$1.72B+12.4%
Q3 FY2024Sep 30, 2024$1.45B+34.4%
Q2 FY2024Jun 30, 2024$1.45B+30.0%
Q1 FY2024Mar 31, 2024$1.34B+26.9%
Q4 FY2023Dec 31, 2023$1.53B+15.9%
Q3 FY2023Sep 30, 2023$1.08B-3.0%
Q2 FY2023Jun 30, 2023$1.11B+7.1%
Q1 FY2023Mar 31, 2023$1.06B+10.3%
Q4 FY2022Dec 31, 2022$1.32B-1.8%
Q3 FY2022Sep 30, 2022$1.11B+15.0%
Q2 FY2022Jun 30, 2022$1.04B-15.5%
Q1 FY2022Mar 31, 2022$959.00M-9.7%
Q4 FY2021Dec 31, 2021$1.35B+39.8%
Q1 FY2021Mar 31, 2021$967.00M+1.6%
Q4 FY2020Dec 31, 2020$1.23B+33.0%
Q3 FY2020Sep 30, 2020$1.06B+20.8%
Q2 FY2020Jun 30, 2020$964.00M-18.4%
Q1 FY2020Mar 31, 2020$952.00M+2.8%
Q2 FY2019Jun 30, 2019$924.00M+6.3%
Q1 FY2019Mar 31, 2019$879.00M+15.7%
Q4 FY2018Dec 31, 2018$1.18B+13.3%
Q3 FY2018Sep 30, 2018$926.00M+5.6%
Q2 FY2018Jun 30, 2018$869.00M-0.5%
Q1 FY2018Mar 31, 2018$760.00M-1.2%
Q4 FY2017Dec 31, 2017$1.04B-3.2%
Q3 FY2017Sep 30, 2017$877.00M-11.4%
Q2 FY2017Jun 30, 2017$873.00M-3.0%
Q1 FY2017Mar 31, 2017$769.00M–
Q4 FY2016Dec 31, 2016$1.08B–
Q3 FY2016Sep 30, 2016$990.00M–
Q2 FY2016Jun 30, 2016$900.00M–

More Amgen figures

See a number that looks wrong?